Trial Profile
A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms UNVEIL
- Sponsors Amgen; Celgene Corporation
- 12 Sep 2018 According to a Celgene Corporation media release, results of a post hoc sub-analysis of data from the ESTEEM 1 and 2 and phase 4 UNVEIL trials were presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress.
- 09 May 2017 Status changed from active, no longer recruiting to completed.
- 05 Mar 2017 Results presented at the American Academy of Dermatology's Annual Meeting 2017, according to a Celgene Corporation media release.